



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q73675

Etsuko KADOWAKI, et al.

Appln. No.: 10/540,028

Group Art Unit: 1713

Confirmation No.: 8868

Examiner: Peter D. Mulcahy

Filed: June 22, 2005

For:

CURABLE COMPOSITION, CURED PRODUCT THEREOF, MOLDED PRODUCT

THEREOF AND USE AS FUEL CELL SEPARATOR

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. §§ 1.97 and 1.98</u>

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003. An Office Action issued in the corresponding Chinese application is also submitted herewith, as is an English translation of the text thereof. Applicants note that one of the references cited in the Office Action (US 2002/0086198 A1) was already disclosed in the Information Disclosure Statement filed June 22, 2005, and thus is not being disclosed again.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT

U.S. Application No.: 10/540,028

Attorney Docket No. Q73675

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required. However, since a

statement can be filed, one is being filed in the event an Office Action has been issued but not

yet received.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents, together with an

English-language version (if not already included) of at least that portion of the Communication

indicating the degree of relevance found by the foreign patent office.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant submits the following explanations: The citing of the

corresponding US Patent No. 6,403,727 B1 and the submission of the corresponding English

language abstract of DE19753302 for CN 1280587 A constitutes a concise statement of

relevance of CN 1280587 A.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 33,725

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 19, 2007

2



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q73675

Etsuko KADOWAKI, et al.

Appln. No.: 10/540,028

Group Art Unit: 1713

Confirmation No.: 8868

Examiner: Peter D. Mulcahy

Filed: June 22, 2005

For:

CURABLE COMPOSITION, CURED PRODUCT THEREOF, MOLDED PRODUCT

THEREOF AND USE AS FUEL CELL SEPARATOR

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: April 19, 2007

Bruce E. Kramer

Registration No. 33,725

Bung 1 Cram

Ark . 9 2007

Substitute for Form 1449 A & B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Сотр	Complete if Known			
Application Number	10/540,028			
Confirmation Number	8868			
Filing Date	June 22, 2005			
First Named Inventor	Etsuko KADOWAKI			
Art Unit	1713			
Examiner Name	Peter D. Mulcahy			
Attorney Docket Number	Q73675			

	U.S. PATENT DOCUMENTS						
Examiner	Cite No. ¹	Document Number		Publication Date			
Initials*		Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		US 6,403,727	Bl	06-11-2002	Leube et al.		
		US					
		US					
		US					
1		US					
		US					
		US					
		US					
		US					

			F	OREIGN PA	TENT DOCUM	ENTS	
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		CN	1280587	A	01-17-2001	BASF AG (DE)	Corresponding English language abstract of DE19753302 & corresponding US Patent No. 6,403,727 cited above
			-				
	-						
			NON	DATENTE LY	L TERATURE DO	CHMENTS	<u> </u>
		I Include no					T
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			Translation ⁶		
				,			
					**		

ı			
ı			
ı	Examiner Signature	Date Considered	
ı	Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.